MX361618B - Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas. - Google Patents

Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.

Info

Publication number
MX361618B
MX361618B MX2011010311A MX2011010311A MX361618B MX 361618 B MX361618 B MX 361618B MX 2011010311 A MX2011010311 A MX 2011010311A MX 2011010311 A MX2011010311 A MX 2011010311A MX 361618 B MX361618 B MX 361618B
Authority
MX
Mexico
Prior art keywords
making
methods
same
pharmaceutical formulations
derivatives
Prior art date
Application number
MX2011010311A
Other languages
English (en)
Other versions
MX2011010311A (es
Inventor
Teofilo Cardoso De Vasconcelos
Ricardo Jorge Dos Santos Lima
Pedro Miguel Da Costa Barrocas
Ligia Sofia De Castro Pereira
Rui Cerdeira De Campos Costa
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of MX2011010311A publication Critical patent/MX2011010311A/es
Publication of MX361618B publication Critical patent/MX361618B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente descripción se refiere a composiciones y formulaciones farmacéuticas que comprenden por lo menos un ingrediente farmacéutico activo seleccionado de derivados de nitrocatecol de la fórmula I como se definen en este documento y sales, ésteres, hidratos, solvatos y otros derivados de los mismos y métodos para hacer las mismas.
MX2011010311A 2009-04-01 2010-03-31 Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas. MX361618B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16579409P 2009-04-01 2009-04-01
PCT/PT2010/000015 WO2010114405A2 (en) 2009-04-01 2010-03-31 Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same

Publications (2)

Publication Number Publication Date
MX2011010311A MX2011010311A (es) 2012-03-07
MX361618B true MX361618B (es) 2018-12-13

Family

ID=42229943

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011010311A MX361618B (es) 2009-04-01 2010-03-31 Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.

Country Status (15)

Country Link
US (3) US20100256194A1 (es)
EP (1) EP2413913B1 (es)
JP (2) JP5864410B2 (es)
KR (1) KR101824257B1 (es)
CN (2) CN105816456A (es)
AU (1) AU2010231962B2 (es)
BR (1) BRPI1016132B8 (es)
CA (1) CA2757418C (es)
DK (1) DK2413913T3 (es)
ES (1) ES2915698T3 (es)
MX (1) MX361618B (es)
PL (1) PL2413913T3 (es)
PT (1) PT2413913T (es)
RU (1) RU2550133C2 (es)
WO (1) WO2010114405A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1907382T3 (en) 2005-07-26 2015-08-31 Bial Portela & Ca Sa Nitrocatecholderivater comt inhibitors as
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
AU2007346018A1 (en) 2007-01-31 2008-08-07 Bial - Portela & Ca, S.A. Dosage regimen for COMT inhibitors
WO2009116882A1 (en) 2008-03-17 2009-09-24 Portela & Ca., S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol
KR102329271B1 (ko) 2009-04-01 2021-11-22 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2791134B1 (en) 2011-12-13 2019-09-25 BIAL - Portela & Cª S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
NO2699580T3 (es) 2014-01-24 2018-02-24
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
EA202091259A1 (ru) * 2017-12-18 2020-09-22 Юникем Лабораториз Лтд Способ получения опикапона и его интермедиатов
KR20210014621A (ko) * 2018-03-01 2021-02-09 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를 포함하는 약학 조성물
CA3112994A1 (en) 2018-10-05 2020-04-09 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
US20210338651A1 (en) 2018-10-05 2021-11-04 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
BR112022017401A2 (pt) 2020-03-13 2022-10-18 Bial Portela & Ca Sa Opicapona micronizada
GB202011709D0 (en) 2020-07-28 2020-09-09 Bial Portela & Ca Sa Solid dispersion of opicapone
GB202016425D0 (en) 2020-10-16 2020-12-02 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
JP2024500754A (ja) 2020-12-17 2024-01-10 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 早期特発性パーキンソン病のための治療レジメン
WO2022180649A1 (en) * 2021-02-26 2022-09-01 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
GB202212082D0 (en) 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1532178A (en) * 1921-07-25 1925-04-07 Louis A Godbold Lubricator
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
US4085563A (en) * 1977-01-31 1978-04-25 Campbell Soup Company Cookie dispensing apparatus
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4368668A (en) * 1981-05-15 1983-01-18 Veb Kombinat Polygraph "Werner Lamberz" Leipzig Printing plate mounting arrangement
US5236952A (en) * 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US6206110B1 (en) * 1996-09-09 2001-03-27 Smith International, Inc. Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit
CA2337755C (en) * 1998-09-18 2008-07-29 Vertex Pharmaceuticals Incorporated Inhibitors of p38
GB2344819A (en) * 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20030027253A1 (en) * 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
KR100891887B1 (ko) * 2001-01-29 2009-04-03 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서 함유하는의약 제제
AU2002313633B2 (en) * 2001-06-08 2007-03-01 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
JP2006516250A (ja) * 2002-12-18 2006-06-29 サイトビア インコーポレイティッド カスパーゼ活性化剤およびアポトーシス誘導物質としての３，５−二置換−［１，２，４］−オキサジアゾールおよびそれらの誘導体ならびにそれらの使用
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
AU2004275470B2 (en) * 2003-09-29 2010-12-02 Novo Nordisk Health Care Ag Improved stability of progestogen formulations
US7300406B2 (en) * 2003-09-30 2007-11-27 Carter Vandette B Medical examination apparatus
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
ATE464303T1 (de) * 2004-04-28 2010-04-15 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20080051441A1 (en) * 2004-12-28 2008-02-28 Astrazeneca Ab Aryl Sulphonamide Modulators
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
EP1888523B1 (en) * 2005-06-03 2011-10-26 Abbott Laboratories Cyclobutyl amine derivatives
JP2007024970A (ja) * 2005-07-12 2007-02-01 Miyakawa:Kk 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置
DK1907382T3 (en) * 2005-07-26 2015-08-31 Bial Portela & Ca Sa Nitrocatecholderivater comt inhibitors as
US20070048384A1 (en) * 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
JP2008162955A (ja) * 2006-12-28 2008-07-17 Chugai Pharmaceut Co Ltd バリン含有高密度顆粒剤
AU2007346018A1 (en) * 2007-01-31 2008-08-07 Bial - Portela & Ca, S.A. Dosage regimen for COMT inhibitors
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
WO2009116882A1 (en) * 2008-03-17 2009-09-24 Portela & Ca., S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol

Also Published As

Publication number Publication date
KR101824257B1 (ko) 2018-01-31
JP2016020369A (ja) 2016-02-04
RU2011143619A (ru) 2013-05-10
CN102438595A (zh) 2012-05-02
DK2413913T3 (da) 2022-06-13
MX2011010311A (es) 2012-03-07
ES2915698T3 (es) 2022-06-24
KR20120008040A (ko) 2012-01-25
JP2012522764A (ja) 2012-09-27
BRPI1016132B1 (pt) 2020-11-24
JP5864410B2 (ja) 2016-02-17
RU2550133C2 (ru) 2015-05-10
WO2010114405A3 (en) 2011-01-06
WO2010114405A2 (en) 2010-10-07
US20190008774A1 (en) 2019-01-10
CN105816456A (zh) 2016-08-03
BRPI1016132A2 (pt) 2016-04-19
AU2010231962A1 (en) 2011-11-17
CA2757418C (en) 2021-06-15
EP2413913B1 (en) 2022-05-18
PT2413913T (pt) 2022-06-09
PL2413913T3 (pl) 2022-09-26
US20210315824A1 (en) 2021-10-14
EP2413913A2 (en) 2012-02-08
AU2010231962B2 (en) 2015-05-21
CN102438595B (zh) 2016-04-27
US20100256194A1 (en) 2010-10-07
CA2757418A1 (en) 2010-10-07
JP6336420B2 (ja) 2018-06-06
BRPI1016132B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
MX2011010311A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
MX2011010415A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
EP2613782A4 (en) INDAZOLE DERIVATIVES AS INHIBITORS OF THE ERK PATHWAY
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
IN2014MN02598A (es)
GEP20227397B (en) Inhibitors of influenza viruses replication
IN2014CN04530A (es)
MX2012000414A (es) Derivados piridin-4-ilo.
MY183312A (en) Pharmaceutical formulation
JO3577B1 (ar) صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt
MX342212B (es) Inhibidores de neprilisina.
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MX2011012523A (es) Esteres cetalicos de anhidropentitoles y usos de los mismos.
MX2013001677A (es) Formulaciones estables de linaclotida.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2009007260A (es) Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
MX2011007451A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
IN2012DN04868A (es)
TN2012000105A1 (en) Spirolactam derivatives and uses of same
EA201270302A1 (ru) Безводные формы производных пиридина
WO2011123524A3 (en) Macrolide inhibitors of mtor
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов

Legal Events

Date Code Title Description
FG Grant or registration